CRISPR Gene Editing: The Molecular Scissors Rewriting Life

The 2020 Nobel Prize. The first approved cure for sickle cell disease in 2023. The He Jiankui scandal. Here is what CRISPR actually does, what it has achieved, and where the ethical lines are.

What CRISPR-Cas9 Actually Does

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring bacterial immune system. Bacteria that survive a viral infection incorporate short sequences from the virus into their DNA — the CRISPR arrays. If the same virus attacks again, the bacteria produce RNA molecules that match the stored sequence, which guide a protein called Cas9 to that sequence and cut the DNA. It's a molecular memory and immune response.

What Jennifer Doudna, Emmanuelle Charpentier, and their colleagues realized — published in a landmark 2012 paper in Science — was that this system could be reprogrammed. By designing a synthetic "guide RNA" with any sequence you want, you can direct Cas9 to cut DNA at any location in any genome. The molecular scissors can be pointed anywhere. Doudna and Charpentier received the Nobel Prize in Chemistry in 2020 for this work.

The First Approved Cure: Sickle Cell Disease

Sickle cell disease affects approximately 100,000 Americans and millions more worldwide, primarily people of African descent. It's caused by a single-letter mutation in the gene encoding hemoglobin, causing red blood cells to form rigid, crescent shapes that block blood vessels and cause severe pain, organ damage, and early death. In December 2023, the FDA approved Casgevy — the first CRISPR-based therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics — for sickle cell disease and beta-thalassemia. The treatment uses CRISPR to reactivate a fetal form of hemoglobin that is naturally switched off after birth, compensating for the defective adult hemoglobin. In clinical trials, 93% of sickle cell patients treated had no severe pain crises for at least 12 months. The cost: approximately $2.2 million per patient.

The He Jiankui Controversy

In November 2018, Chinese biophysicist He Jiankui announced that he had created the world's first gene-edited babies — twin girls, Lulu and Nana, whose embryos he had edited using CRISPR to disable the CCR5 gene, which encodes a protein HIV uses to enter cells. The scientific community's reaction was swift and almost uniformly condemnatory. He had violated multiple ethical principles: the editing was done in human germline cells (changes that would be heritable by all future descendants), the intended benefit (HIV resistance) was achievable by other means, the consent process was inadequate, and he had done it covertly.

He was sentenced to three years in prison by Chinese courts. A third edited baby was later reported. The controversy clarified international consensus: somatic cell editing (in non-reproductive cells, affecting only the patient) is proceeding carefully through clinical trials; germline editing (heritable changes) remains a near-universal ethical line not to be crossed without broad societal deliberation.

Germline vs. Somatic Editing Ethics

The distinction matters enormously. Somatic editing treats a patient's disease without affecting future generations — analogous to any other medical treatment. Germline editing changes the DNA of embryos, which changes the DNA of every cell in the resulting person and every cell of their descendants. This is irreversible in principle and raises issues that somatic editing does not: consent of future persons who cannot consent, potential for heritable enhancement ("designer babies"), and equity concerns about who has access to germline enhancement.

The 2020 National Academies report on heritable human genome editing concluded that germline editing could be considered only after: extensive basic and preclinical research, societal dialogue, regulatory frameworks, and international mechanisms — not before.

FAQ

Q: How precise is CRISPR, and what are the risks of off-target edits?

A: CRISPR-Cas9 is highly precise but not perfect. Off-target cuts — where the guide RNA directs Cas9 to unintended locations with similar sequences — can occur. The frequency depends heavily on guide RNA design and delivery method. Newer variants (base editors, prime editors) improve precision significantly. For therapeutic applications, extensive sequencing of edited cells is required to characterize off-target effects before clinical use. The clinical data from approved therapies to date shows the approach is safe enough for use, with ongoing monitoring.

Q: Could CRISPR be used to eliminate hereditary diseases from the human population entirely?

A: Theoretically, germline editing could eliminate conditions like Huntington's disease (caused by a single dominant mutation) from family lines. The practical and ethical challenges are substantial: most heritable diseases involve many genes, often also associated with protective effects in some environments (sickle cell trait protects against malaria; cystic fibrosis heterozygotes may have some resistance to cholera). The human genome is not a simple program where deleting one line fixes a bug. Broad germline elimination programs would require governance infrastructure that doesn't exist and would raise profound questions about human diversity and who decides what counts as a disease.

Curious minds belong together. Find people who ask the same questions on Good People Map.